Cargando…

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants

BACKGROUND: No scores presently exist to predict bleeding in atrial fibrillation (AF) populations using direct oral anticoagulants (DOACs). We used data from two independent healthcare claims databases to develop and validate a predictive model of major bleeding in a contemporary AF population. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claxton, J’Neka S., MacLehose, Richard F., Lutsey, Pamela L., Norby, Faye L., Chen, Lin Y., O’Neal, Wesley T., Chamberlain, Alanna M., Bengtson, Lindsay G. S., Alonso, Alvaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130859/ https://www.ncbi.nlm.nih.gov/pubmed/30199542 http://dx.doi.org/10.1371/journal.pone.0203599

Ejemplares similares

Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
por: Chen, Nemin, et al.
Publicado: (2018)

Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation
por: O'Neal, Wesley T., et al.
Publicado: (2018)

Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation
por: O’Neal, Wesley T., et al.
Publicado: (2019)

Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants
por: Shao, Iris Yuefan, et al.
Publicado: (2021)

Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database
por: Subramanya, Vinita, et al.
Publicado: (2021)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Association of household income and adverse outcomes in patients with atrial fibrillation
por: LaRosa, Anna Rose, et al.
Publicado: (2020)

Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation
por: Chen, Nemin, et al.
Publicado: (2020)

Claims‐Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism
por: Alonso, Alvaro, et al.
Publicado: (2021)

Association of arterial stiffness with incident atrial fibrillation: a cohort study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2021)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
por: Zakai, Neil A., et al.
Publicado: (2021)

Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)

Joint Associations of Obesity and NT‐proBNP With the Incidence of Atrial Fibrillation in the ARIC Study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2019)

Inpatient Versus Outpatient Acute Venous Thromboembolism Management: Trends and Postacute Healthcare Utilization From 2011 to 2018
por: Lutsey, Pamela L., et al.
Publicado: (2021)

Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in The Atherosclerosis Risk in Communities study
por: Rattani, Anas, et al.
Publicado: (2019)

Autoimmune disease and risk of postpartum venous thromboembolism
por: Walker, Rob F., et al.
Publicado: (2023)

Sleep Apnea, Sleep Duration and Brain MRI Markers of Cerebral Vascular Disease and Alzheimer’s Disease: The Atherosclerosis Risk in Communities Study (ARIC)
por: Lutsey, Pamela L., et al.
Publicado: (2016)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Impact of Atrial Fibrillation on Healthcare Utilization in the Community: The Atherosclerosis Risk in Communities Study
por: Bengtson, Lindsay G. S., et al.
Publicado: (2014)

Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC‐NCS)
por: Alonso, Alvaro, et al.
Publicado: (2017)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Endogenous Carbamylation of Renal Medullary Proteins
por: Claxton, J'Neka S., et al.
Publicado: (2013)

Systems-level analysis reveals selective regulation of Aqp2 gene expression by vasopressin
por: Sandoval, Pablo C., et al.
Publicado: (2016)

Impact of anticoagulants on the clinical outcomes of colonic diverticular bleeding comparing warfarin and direct oral anticoagulants
por: Chang, Li-sa, et al.
Publicado: (2022)

Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management
por: Bahbahani, Hamad, et al.
Publicado: (2018)

Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study
por: Almuwaqqat, Zakaria, et al.
Publicado: (2019)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
por: Andrade, Marcus Vinicius Santos, et al.
Publicado: (2018)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants
por: Yanagisawa, Naohiro, et al.
Publicado: (2018)

Weight change over 9 years and subsequent risk of venous thromboembolism in the ARIC cohort.
por: French, Simone A., et al.
Publicado: (2020)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies
por: Wang, Yimin Pearl, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qjncci55uepp8hg4svfgc28a3i